These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9571357)

  • 1. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
    Elkeles RS; Diamond JR; Poulter C; Dhanjil S; Nicolaides AN; Mahmood S; Richmond W; Mather H; Sharp P; Feher MD
    Diabetes Care; 1998 Apr; 21(4):641-8. PubMed ID: 9571357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative fasting hypoinsulinaemia and ultrasonically measured early arterial disease in type 2 diabetes. The SENDCAP Study Group, St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention Study.
    Elkeles RS; Diamond JR; El-Bahghouti N; Dhanjil S; Nicolaides A; Geroulakos G; Renton S; Anyaoku V; Richmond W; Mather H; Sharp P
    Diabet Med; 1996 Mar; 13(3):247-53. PubMed ID: 8689846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and lipids - a conundrum.
    Valabhji J; Robinson S
    Diabet Med; 2001 Mar; 18(3):250. PubMed ID: 11318849
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
    Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
    Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
    Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study.
    Tanne D; Benderly M; Goldbourt U; Boyko V; Brunner D; Graff E; Reicher-Reiss H; Shotan A; Mandelzweig L; Behar S;
    Am J Med; 2001 Oct; 111(6):457-63. PubMed ID: 11690571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
    Jeck T; Riesen WF; Keller U
    Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF; Dimmitt SB
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease.
    Beishuizen ED; van de Ree MA; Jukema JW; Tamsma JT; van der Vijver JC; Meinders AE; Putter H; Huisman MV
    Diabetes Care; 2004 Dec; 27(12):2887-92. PubMed ID: 15562202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
    Smud R; Sermukslis B
    Curr Med Res Opin; 1987; 10(9):612-24. PubMed ID: 3436157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
    J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention.
    Seviour PW; Teal TK; Richmond W; Elkeles RS
    Diabet Med; 1988 Mar; 5(2):166-71. PubMed ID: 2964984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
    Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
    Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor.
    Tanne D; Koren-Morag N; Graff E; Goldbourt U
    Circulation; 2001 Dec; 104(24):2892-7. PubMed ID: 11739302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.
    Iakobishvili Z; Hasin T; Klempfner R; Shlomo N; Goldenberg I; Brenner R; Kornowski R; Gerber Y
    Mayo Clin Proc; 2019 Jul; 94(7):1171-1179. PubMed ID: 31272567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
    Bezafibrate Infarction Prevention (BIP) study
    Circulation; 2000 Jul; 102(1):21-7. PubMed ID: 10880410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.